<DOC>
	<DOC>NCT02262676</DOC>
	<brief_summary>Depict demographic and clinical features of patients with atrial fibrillation treated with rivaroxaban to prevent stroke and pulmonary embolism in routine clinical practice</brief_summary>
	<brief_title>Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Patients â‰¥ 18 years Patients with atrial fibrillation Patients in treatment with rivaroxaban for stroke prevention in atrial fibrillation at least 3 months previous to inclusion period in study Patients in treatment after start of study Patients treated with other anticoagulant treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Stroke prevention on Atrial Fibrillation</keyword>
	<keyword>Prevention and Control</keyword>
	<keyword>Stroke</keyword>
</DOC>